Pharmacy Integration for Telehealth: 503A, 503B, and Fulfillment Models

General information only. This content is not legal, tax, medical or regulatory advice, and reading it does not create an attorney-client, provider or advisory relationship with Melius Wellness LLC. Melius is a business and operational advisory firm, not a law firm, and does not provide legal services. Laws and regulations vary by state and change often, and this content may not reflect recent changes. Consult qualified healthcare counsel and your tax and clinical advisers before acting on it. Last reviewed: October 2026.

A telehealth visit usually ends with a prescription, and the patient's experience from that point depends almost entirely on the pharmacy. Did the medication arrive quickly? Was it what they expected? Could they reach a pharmacist with a question? For brands that ship medication to patients' homes, choosing and integrating pharmacy partners is one of the most consequential operating decisions they make.

This article explains the main pharmacy models, the regulatory categories that matter, and the questions we help operators think through when building or reviewing their fulfillment setup.

Three common fulfillment models

• Retail routing. The prescription is sent electronically to a pharmacy the patient chooses. This is simple and familiar, but the brand has little control over price, availability or experience.
• Mail-order partner pharmacy. The prescription goes to one or more licensed pharmacies that ship directly to patients. This gives the brand much more control over packaging, timing and patient communication, and it is the most common model for consumer telehealth.
• Compounding pharmacy partners. When a clinician determines that a patient needs a medication that is not available commercially in the needed form or strength, a compounding pharmacy may prepare it. Compounding has its own regulatory framework, described below.

Many brands use a combination: commercially available products through a mail-order partner, and compounded preparations only where a prescriber has a documented clinical reason.

503A and 503B: two different kinds of compounders

Federal law recognizes two main pathways for human drug compounding, named after sections of the Federal Food, Drug, and Cosmetic Act.

503A pharmacies are state-licensed pharmacies (or physicians) that compound medications for individual, identified patients based on a valid prescription. They are overseen primarily by state boards of pharmacy and follow the conditions set out in section 503A, including limits on which ingredients can be used and on preparing medications in advance of prescriptions.

503B outsourcing facilities are a separate category created by Congress. They register with the FDA, are subject to federal current good manufacturing practice requirements and FDA inspection, report the products they make, and can produce compounded medications with or without patient-specific prescriptions, for example for supply to healthcare facilities.

The practical differences for a telehealth operator:

• A 503A relationship is built around patient-specific prescriptions and state pharmacy oversight.
• A 503B facility operates under manufacturing-style quality requirements but is a different business with different rules about distribution.
• Neither pathway makes a compounded drug "FDA-approved." Compounded medications do not go through FDA's approval process for safety and effectiveness.

Which model fits depends on the medications, the clinical rationale, the states served and the volume involved. These are questions for your clinical leadership, pharmacy partners and regulatory counsel together.

Licensure: shipping across state lines

A pharmacy that ships to patients in another state generally needs a nonresident pharmacy license or registration in that state, in addition to its home-state license. Requirements differ: some states require a pharmacist-in-charge licensed in that state, inspection reports, specific compounding standards, or accreditation. The National Association of Boards of Pharmacy offers a voluntary Digital Pharmacy accreditation for pharmacies that serve patients online, which some states and online advertising platforms recognize.

For a telehealth brand, the operating rule is straightforward: every pharmacy partner must be properly licensed for every state you ship to, and you should verify that directly rather than rely on a summary. Ask partners for their license list and keep it current, because your clinician licensure and pharmacy licensure need to cover the same map.

E-prescribing and integration

How prescriptions get from your EMR to the pharmacy matters for both safety and speed.

• Standard e-prescribing sends prescriptions through established networks in standard formats. It is reliable and widely supported.
• Direct integrations between your platform and a partner pharmacy can add order status, shipping updates, refill triggers and patient messaging, which make the experience feel seamless.
• Controlled substances require electronic prescribing systems that meet federal requirements for identity proofing and two-factor authentication, along with state-specific rules and federal telemedicine prescribing rules. Many cash-pay brands avoid controlled substances entirely; those that do not need specialist guidance.

Whatever the method, the prescribing decision belongs to the licensed clinician. The technology should make it easy to send the right prescription to the right pharmacy, not steer clinicians toward particular products. See Choosing an EMR for a cash-pay telehealth practice for more on the EMR side.

Questions to ask a pharmacy partner

• Which licenses and registrations do you hold, in which states, and are any under review?
• Are you a 503A pharmacy, a 503B outsourcing facility, or neither? For compounding, what quality standards and testing do you follow?
• How do you receive prescriptions, and what integration options do you support?
• What are your turnaround times, shipping methods and cold-chain capabilities if needed?
• How can patients reach a pharmacist, and how are adverse events and complaints handled?
• What happens to patients if our relationship ends?
• How do you support recalls, shortages and substitutions?

Marketing and patient communication

Pharmacy relationships also shape what a brand can say. The FDA has warned telehealth companies about false or misleading claims when promoting compounded drugs, such as implying a compounded product is FDA-approved, the same as an approved brand-name drug, or made by a different company than it actually is. Patients should know which pharmacy is filling their prescription and how to contact it.

Good practice is to describe compounded medications accurately, avoid comparative claims you cannot support, and make sure marketing never runs ahead of what the clinician and pharmacy can actually deliver.

Financial relationships with pharmacies

Payments between telehealth businesses, clinicians and pharmacies deserve careful review. Arrangements that reward prescription volume, or that send patients to a pharmacy because of a financial interest, can raise anti-kickback, self-referral and state pharmacy-law concerns, particularly where any federal health program is involved. Pharmacy economics should be structured with counsel, documented, and consistent with fair market value for services actually provided. For how this fits into the broader structure, see How the MSO/PC model works.

How we help

We help telehealth and wellness operators design the pharmacy layer: defining requirements, evaluating partner options (we disclose any relationship we have with a pharmacy or platform under consideration), planning integrations with the EMR and patient experience, and building the operating processes around refills, shipping and support. We work alongside your clinical leadership and counsel. See how we engage or contact us.

Frequently asked questions

What is the difference between a 503A pharmacy and a 503B outsourcing facility?

A 503A pharmacy is state-licensed and compounds for individual patients with valid prescriptions. A 503B outsourcing facility registers with the FDA, follows current good manufacturing practice requirements, and can compound with or without patient-specific prescriptions.

Are compounded medications FDA-approved?

No. Compounded medications are not reviewed by the FDA for safety, effectiveness or quality before they are sold, which is why accurate marketing and careful pharmacy selection matter.

Does a mail-order pharmacy need a license in each state it ships to?

Generally, yes. Most states require out-of-state pharmacies to hold a nonresident license or registration, and requirements vary, so verify each partner's licenses for every state you serve.